Literature DB >> 16850027

Dysregulation of renal sodium transporters in gentamicin-treated rats.

M C Sassen1, S W Kim, T-H Kwon, M A Knepper, R T Miller, J Frøkiaer, S Nielsen.   

Abstract

We aimed to investigate the molecular mechanisms underlying the renal wasting of Na(+), K(+), Ca(2+), and Mg(2+) in gentamicin (GM)-treated rats. Male Wistar rats were injected with GM (40 or 80 mg/kg/day for 7 days, respectively; GM-40 or GM-80). The expression of NHE3, Na-K-ATPase, NKCC2, ROMK, NCC, alpha-, beta- and gamma-ENaC, and CaSR was examined in the kidney by immunoblotting and immunohistochemistry. Urinary fractional excretion of Na(+), K(+), Ca(2+), and Mg(2+) was increased and urinary concentration was decreased in both GM-40 and GM-80 rats. In cortex and outer stripe of outer medulla (cortex) in GM-80 rats, the expression of NHE3, Na-K-ATPase, and NKCC2 was decreased; NCC expression was unchanged; and CaSR was upregulated compared to controls. In the inner stripe of outer medulla (ISOM) in GM-80 rats, NKCC2 and Na-K-ATPase expression was decreased, whereas CaSR was upregulated, and NHE3 and ROMK expression remained unchanged. In GM-40 rats, NKCC2 expression was decreased in the cortex and ISOM, whereas NHE3, Na-K-ATPase, CaSR, ROMK, and NCC abundance was unchanged in both cortex and ISOM. Immunoperoxidase labeling confirmed decreased expression of NKCC2 in the thick ascending limb (TAL) in both GM-80- and GM-40-treated rats. Immunoblotting and immunohistochemical analysis revealed increased expression of alpha-, beta-, and gamma-ENaC in cortex in GM-80 rats, but not in GM-40 rats. These findings suggest that the decrease in NKCC2 in TAL seen in response to low-dose (40 mg/kg/day) gentamicin treatment may play an essential role for the increased urinary excretion of Mg(2+) and Ca(2+), and play a significant role for the development of the urinary concentrating defect, and increased urinary excretion of Na(+) and K(+). At high-dose gentamicin, both proximal and TAL sodium transporter downregulation is likely to contribute to this.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16850027     DOI: 10.1038/sj.ki.5001654

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Renal adaptation to gentamicin-induced mineral loss.

Authors:  Chien-Te Lee; Hung Chun Chen; Hwee-Yeong Ng; Li-Wen Lai; Yeong-Hau H Lien
Journal:  Am J Nephrol       Date:  2012-02-25       Impact factor: 3.754

Review 2.  Drug-induced acid-base disorders.

Authors:  Daniel Kitterer; Matthias Schwab; M Dominik Alscher; Niko Braun; Joerg Latus
Journal:  Pediatr Nephrol       Date:  2014-11-05       Impact factor: 3.714

3.  Gentamicin Inhibits Ca2+ Channel TRPV5 and Induces Calciuresis Independent of the Calcium-Sensing Receptor-Claudin-14 Pathway.

Authors:  Wouter H van Megen; Megan R Beggs; Sung-Wan An; Patrícia G Ferreira; Justin J Lee; Matthias T Wolf; R Todd Alexander; Henrik Dimke
Journal:  J Am Soc Nephrol       Date:  2022-01-12       Impact factor: 10.121

Review 4.  Fluid, electrolyte and acid-base disorders associated with antibiotic therapy.

Authors:  R Zietse; R Zoutendijk; E J Hoorn
Journal:  Nat Rev Nephrol       Date:  2009-04       Impact factor: 28.314

5.  Assessment of nutrient supplement to reduce gentamicin-induced ototoxicity.

Authors:  C G Le Prell; C Ojano-Dirain; E W Rudnick; M A Nelson; S J DeRemer; D M Prieskorn; J M Miller
Journal:  J Assoc Res Otolaryngol       Date:  2014-03-04

Review 6.  Gentamicin nephrotoxicity in animals: Current knowledge and future perspectives.

Authors:  Pavle Randjelovic; Slavimir Veljkovic; Nenad Stojiljkovic; Dušan Sokolovic; Ivan Ilic
Journal:  EXCLI J       Date:  2017-03-24       Impact factor: 4.068

7.  Increased Endocytosis of Cadmium-Metallothionein through the 24p3 Receptor in an In Vivo Model with Reduced Proximal Tubular Activity.

Authors:  Itzel Pamela Zavala-Guevara; Manolo Sibael Ortega-Romero; Juana Narváez-Morales; Tania Libertad Jacobo-Estrada; Wing-Kee Lee; Laura Arreola-Mendoza; Frank Thévenod; Olivier Christophe Barbier
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.